BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Debt
Short-term and long-term borrowings combined.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt broadly unchanged from a year ago
Total debt stood at $2.64M at the end of Q1 FY2026, down 0.2% from a year earlier and down 4.4% from the prior quarter. Over 3 fiscal years it compounded at +300.3% a year.
Context
- Total debt amounted to 0.6% of total assets at the end of Q1 FY2026, down 1.1 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -0.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.77M USD
- Year-over-year change
- —
- 4-year CAGR
- +194.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.77M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 70.1K | +62.6% |
| FY2022 | 2022-12-31 | 43.11K | +16.6% |
| FY2021 | 2021-12-31 | 36.96K | — |
Total Debt vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -0.2% is the 6th highest of 10, against a peer median of +15.7%.
- Total debt amounts to 0.6% of total assets for BBOT, versus a peer median of 9.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $277.36M USD | +1680.8% | -10.1% | 84.1% | |
| Mar 2026 | $197.09M USD | +57.7% | +9.0% | 77.7% | |
| Mar 2026 | $166.3M USD | -70.5% | +29.7% | 54.5% | |
| Sep 2026 | $146.56M USD | +135.6% | -5.4% | 70.0% | |
| Aug 2026 | $65.33M USD | +15.7% | +67.0% | 5.5% | |
| Jun 2026 | $65.21M USD | -4.0% | +46.6% | 9.0% | |
| Sep 2026 | $31.18M USD | -10.3% | -6.5% | 3.0% | |
SEPNSepterna, Inc. | Sep 2026 | $21.99M USD | -8.8% | +221.6% | 3.6% |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $2.64M USD | -0.2% | +300.3% | 0.6% |
| Mar 2026 | CHF 2.24M CHF | +103.2% | -73.4% | 0.9% | |
| Peer median (excluding BBOT) | — | +15.7% | +9.0% | 9.0% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.